债务 更改
AbbVie USD 67.5B 67.5B 2025-12
Agenus USD 35.54M 2.34M 2025-03
Amgen USD 54.6B 17M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Celldex Therapeutics USD 2.34M 285K 2025-12
CSL USD 11.96B 219M 2024-12
Eli Lilly USD 42.5B 3.6M 2025-12
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 17.75B 396M 2025-09
Incyte USD 39.43M 982K 2026-03
Intrexon USD 0 13.82M 2024-06
J&J USD 47.93B 2.14B 2025-12
Jiangsu Hengrui CNY 74.23M 17.2M 2025-12
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
MacroGenics USD 37.01M 238K 2025-09
Merck EUR 12.1B 2.7B 2025-09
Merck USD 49.34B 7.97B 2025-12
Northwest Biotherapeutics USD 32.94M 6.93M 2023-09
Novartis USD 47B 11.62B 2026-03
Novavax USD 233.31M 4.23M 2024-09
Pfizer USD 63.96B 3.11B 2025-12
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sangamo BioSciences USD 0 0 2022-06
Veracyte USD 39.65M 799K 2025-12